The Research Animal Support Facility (RASF) has been a shared resource since the original Cancer Center Support Grant (CCSG) was awarded in 1975. The University of Texas M.D. Anderson Cancer Center has supported the RASF over these years, using institutional funds for the acquisition of major operational equipment and for remodeling and utility upgrades. The RASF has two distinct sites. One is within the perimeter of the Texas Medical Center, and the other is approximately 1 mile south of the Texas Medical Center at the Smith Research Building. Both animal facilities are accredited by the Association for Assessment and Accreditation of Laboratory Animal Core International, have an approved Animal Welfare Assurance Form (A3343-01), and are part of a research facility registered with the United States Department of Agriculture (74-R-065). The RASF is composed of three specific-pathogen-free (SPF) general rodent barriers, an SPF transgenic mouse barrier, a biohazard-use facility, conventional rodent housing, large-animal housing (for monkeys, dogs, pigs, and rabbits) and quarantine facilities. The RASF maintains approximately 37,000 animals daily; 98% are rodents, most of which are mice. The remaining 2% are monkeys, dogs, pigs, rabbits, guinea pigs, hamsters, and frogs. Also used are sea urchins and fruit flies. Animals are used to answer questions about how to diagnose, treat, and prevent cancer and to understand its causes. Investigators in all 13 research departments and in 24 of 29 clinical departments are supported by the RASF. In addition, clinical, surgical, diagnostic imaging,, and irradiation facilities and services are provided, as are diagnostic and pathology laboratory facilities and services. Specific SPF facilities for severe combined immuno-deficiency (SCID) mice use are also provided, and new, expanded SPF facilities for knockout and transgenic mice production and use are being developed, with occupancy expected in about April, 1998.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-26
Application #
6481851
Study Section
Project Start
2001-08-01
Project End
2002-06-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
$254,104
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Yu, Yao; Hu, Hao; Chen, Jiun-Sheng et al. (2018) Integrated case-control and somatic-germline interaction analyses of melanoma susceptibility genes. Biochim Biophys Acta Mol Basis Dis 1864:2247-2254
Melancon, Marites P; Appleton Figueira, Tomas; Fuentes, David T et al. (2018) Development of an Electroporation and Nanoparticle-based Therapeutic Platform for Bone Metastases. Radiology 286:149-157
Zhao, Hui; Zhang, Ning; Ho, Vivian et al. (2018) Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011. Cancer 124:679-687
Pan, Hubert Y; Jiang, Jing; Hoffman, Karen E et al. (2018) Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. J Clin Oncol 36:1823-1830
Grossberg, Aaron J; Mohamed, Abdallah S R; Elhalawani, Hesham et al. (2018) Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Sci Data 5:180173
Lu, Zhimin; Hunter, Tony (2018) Metabolic Kinases Moonlighting as Protein Kinases. Trends Biochem Sci 43:301-310
Beadnell, Thomas C; Nassar, Kelsey W; Rose, Madison M et al. (2018) Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer. Oncogenesis 7:23
Chen, Xiuhui; Mangala, Lingegowda S; Rodriguez-Aguayo, Cristian et al. (2018) RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev 37:107-124
Kono, Miho; Fujii, Takeo; Matsuda, Naoko et al. (2018) Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. J Cancer 9:3640-3646
Khouri, Issa F; Fernandez Curbelo, Irina; Turturro, Francesco et al. (2018) Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clin Cancer Res 24:1011-1018

Showing the most recent 10 out of 12418 publications